Learn More
This study examined the pathological complete response (pCR) rate and safety of sequential gemcitabine-based combinations in breast cancer. We also examined gene expression profiles from tumour(More)
BACKGROUND Neoadjuvant chemotherapy (NACT) is being increasingly used for patients with large-size operable breast cancer. This phase 2 study of sequential NACT with gemcitabine and doxorubicin (Gem(More)
TPS112 Background: Resistance to endocrine therapy (ET) is a common challenge in breast cancer. In treatment regimes involving exemestane, combination therapy employing MM-121 presents the potential(More)
  • 1